Genoskin Secures $8.7M To Expand Human Skin Models As Sustainable Alternative To Animal Testing

The company offers a scalable, sustainable alternative to animal testing. Using donated human skin and proprietary preservation technology, Genoskin maintains live immunocompetent ex vivo platforms for up to seven days post-surgery, enabling more predictive, human-relevant testing than traditional animal or engineered models.

These platforms generate large-scale multiomics datasets, analyzed with AI and advanced bioinformatics, delivering actionable insights into product efficacy and toxicity in humans. Backed by a robust IP portfolio, established tissue sourcing network, and scalable service model, Genoskin provides translational insights that improve regulatory acceptance and predictability for biopharma, cosmetics, and cell and gene therapy companies.

Read Also - Nofence Raises Over €30M Funding In Series B Round

The funding round was led by OCCTE (FPCI Occidev Impacts) with participation from Captech Santé, GSO Innovation, and CA Toulouse 31 Initiatives. It includes $5.4M in equity and $3.3M (€3M) in non-dilutive financing from Bpifrance and banking partners BNP Paribas, Caisse d’Epargne Midi-Pyrénées, and Crédit Agricole.

“As a company built on ethical innovation, we are proud to offer sustainable, human-relevant alternatives to animal testing. This investment validates our strategy and reinforces our position as a leader in predictive immunotoxicology using live human skin models,” said Pascal Descargues, Ph.D., CEO of Genoskin.

“With the support of our investors, Genoskin is well-positioned to drive meaningful change in how biotherapies are developed, ultimately bringing safer treatments to patients worldwide.”

“We are proud to support Genoskin, a company that perfectly embodies our mission to invest in local innovators delivering sustainable solutions with global reach. Genoskin’s technology offers an ethical, scalable alternative to animal testing and pursues a growth strategy that aligns strongly with our values of economic resilience and scientific impact,” said Julien Gomis, managing partner at OCCTE. “

Captech Santé is pleased to contribute to the financing of Genoskin, a company capable of setting new global standards in the development of injectable drugs and that already counts most major global pharmaceutical companies among its clients,” added Alexandre Demailly, investor at Captech Santé. As part of this round, Genoskin welcomes to its Board of Directors: Julien Gomis (OCCTE), Alexandre Demailly (Captech Santé), Emmanuelle Ostiari (OCCTE), and Anaïs Raluy (GSO/CAT31i).

The funding will fuel Genoskin’s next growth phase, supporting staff expansion with plans to double the company’s size within three years and extend its commercial presence in key global markets, including strategic hires in Europe and Asia by 2026.

Genoskin aims to launch new immune-focused services by 2027 and enhance its scientific and regulatory leadership through biosimulation platforms and novel human immune models further reducing reliance on animal testing.

Operations will also scale via industrial automation and increased production capacity in the U.S. and France, with expanded facilities opening in Salem, MA (2026) and Toulouse, France (2027). This expansion will double skin model production and introduce next-day delivery of fresh human primary mast cells in the U.S.

About Genoskin

Founded in 2011, Genoskin leverages expertise in skin biology and immunology to provide human-relevant data for therapeutics, vaccines, medical devices and cosmetics. Using donated skin preserved up to seven days, its proprietary platforms enable comprehensive testing across all cell types and structures, delivering reliable insights that accelerate research and development.